Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Horst Dr Lindhofer"'
Publikováno v:
Virology. 214:624-627
The processing of the HIV-1 Pr160gag-polprecursor polyprotein was analyzed in freshly HIV-1-infected MT-4 cultured cells. Single intermediates of the processing cascade were characterized by immunoblotting using distinct antisera. A potent inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::484c2536ddd3f4affc0392f49a054110
https://doi.org/10.1006/viro.1995.0074
https://doi.org/10.1006/viro.1995.0074
Publikováno v:
Eur. J. Immunol. 25, 2242-2246 (1995)
Formation of anti-antibodies (anti-Ab) is known to counteract immunotherapy with anti-T cell antibodies. Our previously described immunological approach prevented anti-Ab with the consequence of prolonged survival of fully mismatched skin grafts in C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c23c79096d0507a87536b2f1eb38cd0
https://doi.org/10.1002/eji.1830250819
https://doi.org/10.1002/eji.1830250819
Autor:
Josef Eberle, B. Kranz, Hans Nitschko, Hermann M. Schätzl, K. Von Der Helm, G. Deby, Horst Dr Lindhofer
Publikováno v:
Antiviral Chemistry and Chemotherapy. 5:236-242
An HIV-infected cell culture was treated with the specific HIV proteinase inhibitor Ro 31-8959 for three months to analyse the antiviral effect and possible cytotoxicity of the drug in long-term treatment. The drug was added 1 h after HIV infection w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7d6c078a1110fb8676b63a9960a8c2d
https://doi.org/10.1177/095632029400500405
https://doi.org/10.1177/095632029400500405
Publikováno v:
Blood. 88(12)
Despite improved procedures in chemotherapy and bone marrow transplantation (BMT), post-BMT leukemia relapse rates have remained rather constant in the last decade. Immunotherapy with monoclonal or bispecific antibodies (bsAb) is a promising approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e506e239184cd366a0fa8f47009882
https://pubmed.ncbi.nlm.nih.gov/8977258
https://pubmed.ncbi.nlm.nih.gov/8977258
Publikováno v:
Scopus-Elsevier
Bispecific monoclonal antibodies (bsAbs) are a promising immunotherapeutic option for treatment of cancer, especially in situations of minimal residual disease. The combination of an anti-CD3 and anti-tumor-associated antigen antibody redirects cytot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a406f93e964fb6b827499c650205cb79
http://www.scopus.com/inward/record.url?eid=2-s2.0-0034978614&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0034978614&partnerID=MN8TOARS
